Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ejheart.2005.03.012
Title: Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model
Authors: Ye, L. 
Sim, E.K.W. 
Haider, H.Kh. 
Jiang, S.
Ling, L.H. 
Ge, R. 
Law, P.K.
Keywords: Angiogenesis
Cryoinjury
Gene therapy
Myoblast
Myogenesis
Issue Date: 2005
Source: Ye, L., Sim, E.K.W., Haider, H.Kh., Jiang, S., Ling, L.H., Ge, R., Law, P.K. (2005). Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model. European Journal of Heart Failure 7 (6) : 945-952. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejheart.2005.03.012
Abstract: Background: We hypothesized that combination therapy using human myoblasts and VEGF165 will lead to better prognosis in a failing heart. Methods: Forty-eight female Wistar rats with cryoinjured hearts were randomized into non-treated normal (group-1, n = 12), DMEM injected (group-2, n = 10), myoblast-transplanted (group-3, n = 12) and myoblast-hVEGF165 (group-4, n = 14). Ten days after cryoinjury, 200 μl DMEM containing 3 × 106 cells or without cells was injected into the injured myocardium. Animals were maintained on cyclosporine for 6 weeks post cell transplantation. Heart function was assessed by echocardiography. Animals were sacrificed and hearts were processed for histochemical and immunohistochemical studies. Results: Histological examination showed survival of the donor myoblasts expressing lac-z and hVEGF165 in rat cardiac tissue. Fluorescent immunostaining for vWillebrand Factor-VIII and smooth muscle actin expression at low power microscope (× 100) showed significantly higher blood vessel density in group-4 (31.25 ± 1.82; 24.63 ± 0.92) as compared to group-2 (13.29 ± 1.0; p < 0.001; 9.71 ± 0.81, p < 0.001) and group-3 (16.50 ± 1.43, p < 0.001; 14.5 ± 1.34, p < 0.001). Echocardiography showed that ejection fraction and fractional shortening of group-3 (93.36 ± 1.52%, p = 0.005; 75 ± 3.75%, p = 0.024) and group-4 (94.8 ± 1.62%, p = 0.003; 76.13 ± 2.15%, p = 0.011) significantly improved as compared to group-2 (81.8 ± 3.3%, 55.1 ± 7.18%). Conclusion: Myoblasts carrying of hVEGF165 are potential therapeutic transgene carriers for cardiac repair. © 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Source Title: European Journal of Heart Failure
URI: http://scholarbank.nus.edu.sg/handle/10635/30194
ISSN: 13889842
DOI: 10.1016/j.ejheart.2005.03.012
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

22
checked on Dec 13, 2017

WEB OF SCIENCETM
Citations

20
checked on Nov 16, 2017

Page view(s)

192
checked on Dec 10, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.